other studies in the phase III program of secukinumab 1,2 . Major difference is represented by the high number of biological-experienced patients and comorbidities. Potential differences between these real world results and previously obtained phase III results will have to be discussed to assess their impact on patients.
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[2] Baeten D et al. Lancet. 2013; 382(9906) Data was extracted using a form developed for this specific purpose. The quality of the studies was assessed based on CEBM Oxford. Clinical response in patients who switched to a second bDMARD was determined and compared with the one achieved after receiving the first bDMARD (a TNFi in all cases). Results are shown as median (range) and relative frequencies (%). Results: In total, 7 studies out of 1506 retrieved citations were included. All studies included patients with ankylosing spondylitis (AS). The study design was prospective observational (n=3), retrospective observational (n=2), open-label trial (n=1) and post-hoc analysis from two RCTs (n=1). The level of evidence for all the studies was 4. In these studies, a total of in 4678 patients received a first bDMARD and 1198 patients switched to a second bDMARD (a TNFi in all cases except in 51 patients that switched to secukinumab). Baseline characteristics of patients included in the studies were: 41 (38-44) years old, 67% (64-74) males, 78% (74-89) HLA-B27+ and BASDAI before switching 6.2 (5.3-6.5). The most frequent reason to switch bDMARD was inefficacy, followed by intolerance/adverse events. Median (range) time to assess response after switching was 6 (3-12) months. The criteria to define clinical response were heterogeneous. BASDAI50 was employed in four studies and the percentage of patients who achieved this response after the first and the second bDMARD for each study was: (63% vs 41%), (50% vs 28%), (54% vs 37%), (72% vs 56%), respectively. The response for the other three studies was based on different definitions, being as follows: BASDAI <4 (83% vs 78%), ASAS20 response (67% vs 48%) and retention rate after one year (65% vs 60%). The reason to switch bDMARD (intolerance or inefficacy) was not found as a significant predictor of treatment response in most of the studies. In addition, two studies reported data (n=137 and 11 patients) to evaluate the efficacy of switching to a third bDMARD (TNFi in both cases). The percentage of patients who responded (BASDAI50) to the third TNFi was 30% and 52%, respectively.
Conclusions:
In patients with AS who do not respond to a first TNFi, switching to another bDMARD (either a TNFi or secukinumab) is efficacious in a considerable number of patients (30-50%). However, the clinical response after receiving a second bDMARD is lower to the one experienced after the first TNFi. Published data for switching to a third bDMARD is very limited. Background: Rapid and sustained improvements in the signs and symptoms of ankylosing spondylitis (AS) have been reported with secukinumab, a fully human anti-IL-17A mAb, over the first 2 years (yrs) in the Phase 3 MEASURE 1 trial.
1,2
Objectives: To report efficacy and safety of secukinumab through 3 yrs in an extension trial (NCT01863732) to the core MEASURE 1 trial. Methods: After the 2-yr core trial, patients (pts) receiving secukinumab 150 or 75mg s.c. were invited to enter a 3-yr extension trial. Efficacy results at Week (Wk) 156 are reported for pts who were originally randomised to secukinumab. Assessments at Wk 156 included ASAS20/40, BASDAI, BASDAI50, SF-36 PCS, ASAS partial remission (ASAS PR) and ASDAS-CRP. Binary and continuous variables used multiple imputation and MMRM estimates, respectively. Analyses by anti-TNF use (naïve/intolerant to or inadequate response [IR]) was pre-specified and reported as observed. Safety analyses included all pts who received ≥1 dose of secukinumab. Results: A total of 290/371 pts (78%) completed the 2-yr core trial. Figure) . Similar trends were observed regardless of prior anti-TNF use (Table) . Across the treatment period (secukinumab exposure [mean±SD] : 964.3±372.1 days), exposure-adjusted incidence rate with secukinumab for serious infections, Crohn's disease and malignant/unspecified tumours was 1.1, 0.5 and 0.5 per 100 pt-yrs, respectively. e Evaluable data available in n=70 and 75 pts (naïve) and n=16 and 23 pts (IR) in the secukinumab IV→150mg and IV→75mg groups, respectively. # Observed data provided for reference. IV, pts received secukinumab 10mg/kg i.v. loading at baseline, Wks 2 and 4; N, number of pts in the extension trial.
Conclusions: Secukinumab provided sustained efficacy in signs/symptoms and physical function in pts with active AS over 3 yrs. Secukinumab was well tolerated with a favorable safety profile consistent with that reported previously. 
